Can-Fite BioPharma Ltd. (CANF)
Can-Fite BioPharma Statistics
Share Statistics
Can-Fite BioPharma has 48.79K shares outstanding. The number of shares has increased by 62.34% in one year.
| Shares Outstanding | 48.79K |
| Shares Change (YoY) | 62.34% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 1.57% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,986 |
| FTD / Avg. Volume | 0.67% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.01 and the forward PE ratio is 0.98. Can-Fite BioPharma's PEG ratio is 0.
| PE Ratio | -0.01 |
| Forward PE | 0.98 |
| PS Ratio | 0.06 |
| Forward PS | 0 |
| PB Ratio | 0.01 |
| P/FCF Ratio | -0.01 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Can-Fite BioPharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.38, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.38 |
| Quick Ratio | 4.38 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | -580.71 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $134,800 |
| Profits Per Employee | $-1,576,000 |
| Employee Count | 5 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -48.77% in the last 52 weeks. The beta is 0.46, so Can-Fite BioPharma's price volatility has been higher than the market average.
| Beta | 0.46 |
| 52-Week Price Change | -48.77% |
| 50-Day Moving Average | 1.49 |
| 200-Day Moving Average | 1.98 |
| Relative Strength Index (RSI) | 32.04 |
| Average Volume (20 Days) | 298,196 |
Income Statement
In the last 12 months, Can-Fite BioPharma had revenue of 674K and earned -7.88M in profits. Earnings per share was -32592.
| Revenue | 674K |
| Gross Profit | 674K |
| Operating Income | -8.13M |
| Net Income | -7.88M |
| EBITDA | -8.12M |
| EBIT | -8.13M |
| Earnings Per Share (EPS) | -32592 |
Balance Sheet
The company has 4.83M in cash and 104K in debt, giving a net cash position of 4.72M.
| Cash & Cash Equivalents | 4.83M |
| Total Debt | 104K |
| Net Cash | 4.72M |
| Retained Earnings | -166.36M |
| Total Assets | 9.12M |
| Working Capital | 6.93M |
Cash Flow
In the last 12 months, operating cash flow was -7.64M and capital expenditures -5K, giving a free cash flow of -7.64M.
| Operating Cash Flow | -7.64M |
| Capital Expenditures | -5K |
| Free Cash Flow | -7.64M |
| FCF Per Share | -1.05 |
Margins
Gross margin is 100%, with operating and profit margins of -1206.23% and -1169.14%.
| Gross Margin | 100% |
| Operating Margin | -1206.23% |
| Pretax Margin | -1169.14% |
| Profit Margin | -1169.14% |
| EBITDA Margin | -1205.19% |
| EBIT Margin | -1206.23% |
| FCF Margin | -1133.83% |
Dividends & Yields
CANF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CANF is $10, which is 861.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 861.5% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Jan 9, 2023. It was a backward split with a ratio of 1:10.
| Last Split Date | Jan 9, 2023 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -27.36 |
| Piotroski F-Score | 2 |